If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

Recovery of pure red-cell aplasia secondary to antierythropoietin antibodies after cessation of recombinant human erythropoietin

$48.00 plus tax (Refund Policy)

Download / Buy Article:



We describe a patient with end-stage renal failure (ESRF) who developed anti-erythropoietin (anti-EPO) antibodies and pure red-cell aplasia (PRCA) after using Eprex (Janssen-Cilag, Sydney). Anti-EPO antibodies were detected with an immunoprecipitation technique and were shown to inhibit erythropoiesis in vitro. Antibody levels waned upon ceasing Eprex. The patient required transfusions for 21 months then recovered after immunosuppression. (Intern Med J 2003; 33: 468−471)

Keywords: antierythropoietin antibodies; end stage ­renal failure; pure red-cell aplasia; recombinant human erythropoietin

Document Type: Research Article

DOI: http://dx.doi.org/10.1046/j.1445-5994.2003.00448.x

Affiliations: 1: Nephrology, 2: Haematology and 3: Cardiology, St. Vincent's Hospital, Sydney, New South Wales, Australia

Publication date: September 1, 2003

Related content



Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more